AstraZeneca's Disease Research Cutback Will Not Affect Chinese Market
This article was originally published in PharmAsia News
Executive Summary
Although the ultimate effects of AstraZeneca's 25 percent cutback in disease research remain to be seen, high incidence diseases in China will definitely become a priority for the company